Eric L. Schneider, Ph.D.
Affiliations: | 2005 | University of California, Berkeley, Berkeley, CA, United States |
Area:
catalytic and biological properties of redox enzymesGoogle:
"Eric Schneider"Mean distance: 8.3
Parents
Sign in to add mentor| Michael A. Marletta | grad student | 2005 | UC Berkeley | |
| (Plasmodium falciparum histidine rich protein II: Studies towards understanding heme binding and its potential as an antimalarial target.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Henise J, Fontaine SD, Hearn BR, et al. (2019) In Vitro-In Vivo Correlation for the Degradation of Tetra-PEG Hydrogel Microspheres with Tunable β-Eliminative Crosslink Cleavage Rates International Journal of Polymer Science. 2019: 1-7 |
| Hearn BR, Fontaine SD, Pfaff SJ, et al. (2018) Primary deuterium kinetic isotope effects prolong drug release and polymer biodegradation in a drug delivery system. Journal of Controlled Release : Official Journal of the Controlled Release Society |
| Kara E, Manna D, Løset GÅ, et al. (2017) Analysis of the substrate specificity of Factor VII activating protease (FSAP) and design of specific and sensitive peptide substrates. Thrombosis and Haemostasis. 117 |
| Schneider EL, Hearn BR, Pfaff SJ, et al. (2016) An approach for half-life extension of small antibody fragments that does not affect tissue uptake. Bioconjugate Chemistry |
| Schneider EL, Henise J, Reid R, et al. (2016) Subcutaneously administered self-cleaving hydrogel-octreotide conjugates provide very long-acting octreotide. Bioconjugate Chemistry |
| Schneider EL, Henise J, Reid R, et al. (2016) Hydrogel drug delivery system using self-cleaving covalent linkers for once-a-week administration of exenatide. Bioconjugate Chemistry |
| Schneider EL, Ashley GW, Dillen L, et al. (2015) Half-life extension of the HIV-fusion inhibitor peptide TRI-1144 using a novel linker technology. European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft FüR Pharmazeutische Verfahrenstechnik E.V. 93: 254-9 |
| Santi DV, Schneider EL, Ashley GW. (2014) Macromolecular prodrug that provides the irinotecan (CPT-11) active-metabolite SN-38 with ultralong half-life, low C(max), and low glucuronide formation. Journal of Medicinal Chemistry. 57: 2303-14 |
| Santi DV, Schneider EL, Reid R, et al. (2012) Predictable and tunable half-life extension of therapeutic agents by controlled chemical release from macromolecular conjugates. Proceedings of the National Academy of Sciences of the United States of America. 109: 6211-6 |
| Schneider EL, Lee MS, Baharuddin A, et al. (2012) A reverse binding motif that contributes to specific protease inhibition by antibodies. Journal of Molecular Biology. 415: 699-715 |